TrialCancer2021

Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.

Koji Sasaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.